Create a Free Account
or
Create a Free Account
or
| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
B of A Securities analyst Dimple Gosai maintains Moderna (NASDAQ:MRNA) with a Underperform and lowers the price target from ...
Barclays analyst Gena Wang maintains Moderna (NASDAQ:MRNA) with a Equal-Weight and lowers the price target from $31 to $25.
After a brief and cautious rebound on Wednesday, risk-off sentiment returned sharply on Thursday, with AI-linked stocks leading...
Moderna posts a smaller Q3 loss, trims 2025 sales forecast, cuts R&D costs, and boosts cash outlook as COVID vaccine demand...
Moderna reported third-quarter financial results on Thursday. The transcript from the company's earnings call has been prov...
Moderna (NASDAQ:MRNA) narrows FY2025 sales outlook from $1.500 billion-$2.200 billion to $1.600 billion-$2.000 billion vs $1.89...
Moderna (NASDAQ:MRNA) reported quarterly losses of $(0.51) per share which beat the analyst consensus estimate of $(2.02) by 74...
